(Q47767216)

5 February 2018

title

Effect of YM087, a potent nonpeptide vasopressin antagonist, on vasopressin-induced protein synthesis in neonatal rat cardiomyocyte (English)

1 reference

5 February 2018

0 references

Tahara A

1

1 reference

5 February 2018

Tomura Y

2

1 reference

5 February 2018

Wada K

3

1 reference

5 February 2018

Kusayama T

4

1 reference

5 February 2018

Tsukada J

5

1 reference

5 February 2018

Ishii N

6

1 reference

5 February 2018

Yatsu T

7

1 reference

5 February 2018

Uchida W

8

1 reference

5 February 2018

Tanaka A

9

1 reference

5 February 2018

publication date

1 April 1998

1 reference

5 February 2018

published in

Cardiovascular Research

1 reference

5 February 2018

volume

38

1 reference

5 February 2018

issue

1

1 reference

5 February 2018

page(s)

198-205

1 reference

5 February 2018

Rat angiotensin II (type 1A) receptor mRNA regulation and subtype expression in myocardial growth and hypertrophy

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0008-6363%2897%2900324-6

Specific receptor for endothelin in cultured rat cardiocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-6363%2897%2900324-6

Vasopressin increases cytosolic free [Ca2+] in the neonatal rat cardiomyocyte. Evidence for V1 subtype receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-6363%2897%2900324-6

Hormonal stimulation of phosphatidylinositol breakdown with particular reference to the hepatic effects of vasopressin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-6363%2897%2900324-6

OPC-21268, an Orally Effective, Nonpeptide Vasopressin V1 Receptor Antagonist

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-6363%2897%2900324-6

Radioligand binding studies reveal marked species differences in the vasopressin V1 receptor of rat, rhesus and human tissues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-6363%2897%2900324-6

Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-6363%2897%2900324-6

Biochemical and pharmacological properties of SR 49059, a new, potent, nonpeptide antagonist of rat and human vasopressin V1a receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-6363%2897%2900324-6

Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-6363%2897%2900324-6

Effect of a new V1 antagonist (OPC-21268) on vascular action of vasopressin in cultured rat vascular smooth muscle cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-6363%2897%2900324-6

Inhibition of vasopressin action in vascular smooth muscle by the V1 antagonist OPC-21268

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-6363%2897%2900324-6

Effect of a new, potent, non-peptide V1a vasopressin antagonist, SR 49059, on the binding and the mitogenic activity of vasopressin on Swiss 3T3 cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-6363%2897%2900324-6

Effects of a nonpeptide vasopressin antagonist (OPC-21268) on cytosolic Ca2+ concentration in vascular and cardiac myocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-6363%2897%2900324-6

Pharmacological profile of YM087, a novel nonpeptide dual vasopressin V1A and V2 receptor antagonist, in dogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-6363%2897%2900324-6

Differentiation of rat myocytes in single cell cultures with and without proliferating nonmyocardial cells. Cross-striations, ultrastructure, and chronotropic response to isoproterenol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-6363%2897%2900324-6

Doxorubicin selectively inhibits muscle gene expression in cardiac muscle cells in vivo and in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-6363%2897%2900324-6

Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-6363%2897%2900324-6

Direct identification of the rat hepatocyte arginine8 vasopressin receptor with a radiolabelled V1-selective antagonist

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-6363%2897%2900324-6

Signal transduction of V1-vascular vasopressin receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-6363%2897%2900324-6

Distinct mechanisms of action of V1 antagonists OPC-21268 and [d(CH2)5Tyr(Me)AVP] in mesangial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-6363%2897%2900324-6

Endothelin-1 is an autocrine/paracrine factor in the mechanism of angiotensin II-induced hypertrophy in cultured rat cardiomyocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-6363%2897%2900324-6

Transcriptional activation of the cardiac myosin light chain 2 and atrial natriuretic factor genes by protein kinase C in neonatal rat ventricular myocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-6363%2897%2900324-6

Vasopressin dependent tyrosine phosphorylation of a 38 kDa protein in human platelets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-6363%2897%2900324-6

Mitogen-activated protein kinases: versatile transducers for cell signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-6363%2897%2900324-6

Vasopressin stimulation of mouse 3T3 cell growth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-6363%2897%2900324-6

Arginine vasopressin gene expression in chronic cardiac failure in rats.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-6363%2897%2900324-6

Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-6363%2897%2900324-6

Hemodynamic effects of infused arginine vasopressin in congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-6363%2897%2900324-6

Vasopressin and angiotensin II contribute equally to the increased afterload in rabbits with heart failure.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-6363%2897%2900324-6

Acute hemodynamic effect of a vascular antagonist of vasopressin in patients with congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0008-6363%2897%2900324-6

10.1016/S0008-6363(97)00324-6

7 January 2021

Identifiers

DOI

1 reference

5 February 2018

1 reference

5 February 2018